Latest Health News

Powerhouse Ventures holds $6.14 million in liquid assets and advances new technology fund launch despite challenging market conditions.

Celsius Resources appoints Bardin Davis as MD to lead financing efforts for the MCB Copper-Gold Project, extends Final Investment Decision timeline to late 2026, and navigates a complex ownership dispute in the Philippines while raising A$9.3 million.

Dubber Corporation reported a historic positive underlying operating cashflow run-rate in Q3 FY26, driven by a USD 3.06 million initial payment from a Tier 1 North American communications service provider and ongoing cost reductions. Recurring revenue dipped 6% quarter-on-quarter due to portfolio optimisation and foreign exchange impacts.

EMC Gold is pushing forward with a drilling campaign at its Salave Gold Project while navigating a procedural setback from the High Court of Asturias. The company also surrendered its Ivan Well tenement in WA and maintains a solid cash position of CAD$4.6 million.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Culpeo Minerals has restructured its Lana Corina earn-in deal to slash near-term cash outlays and plans a fully funded 4,000m diamond drilling campaign at Vista Montana in Q2 2026, while advancing its Fortuna copper project and streamlining its shareholder base.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Resonance Health reports strong cash flow and progress in clinical trials, with a record forward order pipeline for its Software-as-a-Medical-Device business and profitable trial site clinics.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.